Athira Issues Statement in Response to Richard A. Kaynes Suspension of His
Proxy Contest
Athira
Board Unanimously Recommends Shareholders Vote FOR its Highly Qualified Nominees Joseph
Edelman, John M. Fluke,
Jr. and Grant Pickering on the WHITE proxy card
BOTHELL, WA, May 16, 2022
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today issued the following statement in response to Richard A.
Kaynes suspension of his proxy contest:
We appreciate the strong support of our shareholders throughout this process and their
recognition of the incredible talent and commitment of the people across Athira. We continue to urge shareholders to vote FOR Athiras three director nominees on the WHITE proxy card.
The Athira board is highly qualified and actively engaged in the development and execution of Athiras strategy. It has been purpose-built
for this phase in the companys evolution. We have the right strategy, as well as the right leadership team and board of directors, to drive Athiras success. As we enter a pivotal chapter, with topline results from the Phase 2 ACT-AD study expected by the end of the second quarter of 2022 and multiple other upcoming clinical milestones, the company will remain focused on doing what is right for Athira, our shareholders, and our patients
and their caregivers. We look forward to an ongoing dialogue with our shareholders as we execute our strategy.
Athiras board urges shareholders to
vote today FOR Athiras three director nominees Joseph Edelman, John M. Fluke, Jr. and Grant Pickering on the WHITE proxy card.
Advisors
Goldman Sachs & Co. LLC is serving as
financial advisor to Athira. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal advisor to Athira.
About Athira Pharma, Inc.
Athira Pharma Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore
neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline therapeutic candidates,
targeting the HGF/MET neurotrophic system, for Alzheimers and Parkinsons disease dementia, Dementia with Lewy bodies and neuropsychiatric indications. For more information, visit www.athira.com. You can also follow Athira on
Facebook, LinkedIn and @athirapharma on Twitter and Instagram.